Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation

Waldo, Albert L.

doi:10.1016/j.ccl.2008.09.002

Cited by 8 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antithrombotic agents studied in Europe and North America include the most familiar vitamin K antagonist warfarin; antiplatelet agents (AP) aspirin; and other AP such as dipyridamole, indobufen, trifusal (1), and clopidogrel (8). Patients with AF should take adequate antithrombotic agents according to the risk stratifications of ischemic stroke (1,2,4,5). All patients with valvular AF and patients with nonvalvular AF in the high risk stratification need long-term anticoagulation therapy.…”

Section: Low Risk Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Underuse of Antithrombotic Therapy Caused High Incidence of Ischemic Stroke in Patients with Atrial Fibrillation

Tsai

Chen

et al. 2011

International Journal of Stroke

View full text Add to dashboard Cite

show abstract

Section: Low Risk Factorsmentioning

confidence: 99%

“…Nonvalvular AF does not have these identifiers (1). AF is the most important cause of ischemic stroke (2, 3). The risk of ischemic stroke will be increased considerably during the 24–48 h post-AF (4).…”

Section: Introductionmentioning

confidence: 99%

Underuse of Antithrombotic Therapy Caused High Incidence of Ischemic Stroke in Patients with Atrial Fibrillation

Tsai

Chen

et al. 2011

International Journal of Stroke

View full text Add to dashboard Cite

show abstract

“…Acute coronary syndromes, ischaemic stroke, atrial fibrillation, pulmonary embolism and deep-vein thrombosis are conditions associated with high morbidity and mortality (1,2). Current prevention or treatment of thromboembolic disorders includes parenteral use of heparin, unfractionated heparin, low-molecular-weight heparins (LMWH), the synthetic pentasaccharide fondaparinux or injectable thrombin inhibitors such as hirudin, bivalirudin and argatroban (3).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats

Pehrsson¹,

Johansson²,

Kjaer³

et al. 2010

Thromb Haemost

View full text Add to dashboard Cite

AZD0837, currently in clinical development, is a once-daily oral anticoagulant that is bioconverted to AR-H067637, a selective, reversible direct thrombin inhibitor (DTI). When developing a new DTI, the antithrombotic effects are commonly investigated in in vivo animal models; this report shows the effect of AR-H067637 in venous and arterial thrombosis and bleeding models in anaesthetised rats. Thrombus formation was induced by topical application of ferric chloride to the carotid artery or to the caval vein with partial stasis. Cutaneous incision bleeding time and muscle transection blood loss were assessed, with or without acetylsalicylic acid (ASA). Activated partial thromboplastin time (APTT), ecarin coagulation time (ECT) and thrombin coagulation time (TCT) were used as plasma biomarkers of anticoagulant effect. Dalteparin was used as a reference compound. AR-H067637, given by continuous infusion, displayed a dose-dependent antithrombotic effect, with 50% inhibition (IC50) of thrombus size in venous and arterial thrombosis models obtained at plasma concentrations of 0.13 μM and 0.55 μM, respectively, without increased bleeding. Dose-dependent increased bleeding and blood loss were seen at plasma concentrations ≥1 μM AR-H067637. At the highest AR-H067637 plasma concentration tested, bleeding time and blood loss increased two and four times the vehicle group. Addition of ASA moderately potentiated bleeding time and blood loss. APTT, ECT and TCT were dose-dependently prolonged. These studies demonstrate that the DTI AR-H067637 inhibits thrombus formation in rat venous and arterial thrombosis models with no or minor increases in bleeding.

show abstract

Management und Therapie des Vorhofflimmerns beim geriatrischen Patienten

et al. 2012

View full text Add to dashboard Cite

Among geriatric patients, atrial fibrillation is the most common cardiac arrhythmia. In patients over 80 years of age, the prevalence rises to approximately 10%. Atrial fibrillation is associated with serious health implications, including a 2-fold increase in mortality risk and a 5-fold increase in stroke risk. In contrast to these facts, the current guidelines on the management of atrial fibrillation of the European Society of Cardiology (ESC) contain only a short paragraph on these patients. Many relevant clinical aspects go without any comment. Thus, the purpose of our paper is to discuss those special needs of geriatric patients and their physicians which are not mentioned in the guidelines of the ESC. In our review, we discuss rhythm versus rate control, oral anticoagulation, outcome, prevention, falls, adherence, polypharmacy, dementia, nursing home patients, frailty, and geriatric assessment in consideration of geriatric patients. An extended search of the literature on Pubmed served as the basis for this review. Individual aspects of each geriatric patient should be considered when managing these complex patients; however, the complexity of each case must not lead to an individualized therapy that is not in accordance with current guidelines and the literature. A large number of papers which help us to answer most of the clinical questions regarding the management of trial fibrillation in geriatric patients have already been published.

show abstract

Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation

Cited by 8 publications

References 44 publications

Underuse of Antithrombotic Therapy Caused High Incidence of Ischemic Stroke in Patients with Atrial Fibrillation

Underuse of Antithrombotic Therapy Caused High Incidence of Ischemic Stroke in Patients with Atrial Fibrillation

Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats

Management und Therapie des Vorhofflimmerns beim geriatrischen Patienten

Contact Info

Product

Resources

About